Drug discounting to insurers soars from 28% to 41% in 5 years, with no end in sight: report

23rd January 2018 Uncategorised 0

With drug companies discounting their products more than ever before to win better deals with payers, list prices mean less. But those discounts are likely to keep growing, analysts predict, and investors should worry about their long-term effects on the pharma bottom line.

More: Drug discounting to insurers soars from 28% to 41% in 5 years, with no end in sight: report
Source: fierce